Hepatitis C cirrhosis: New perspectives for diagnosis and treatment

Table 5 Summary of sofosbuvir trials and enrollment of cirrhotic patients

Trial	Regimen	Duration (wk)	Patient population (patients withcirrhosis in treatment group)	SVR and additionalfindings	SVR for cirrhoticpatients
NEUTRINO[36]	SOF + peg IFN + RBV	12	327 treatment naïve (54) with G1, 4-6	90% overall	80%
			G1: 292	89%
			G4: 28	96%
			G5-6: 7	100%
FISSION[36]	SOF + RBV	12	253/499 treatment naïve with G2, G3 (49 cirrhotic) assigned to treatment arm	67%	47%
			G2: 70/253	97%	91%
			G3: 183/253	56%	34%
POSITRON[37]	SOF + RBV	12	207/278 IFN intolerant or ineligible with G2, G3 (31 cirrhotic) assigned to treatment group	78%	61%
			G2: 109	93%	94%
FUSION[37]	SOF + RBV	12	G3: 98	61%	21%
			100 treatment experienced with G2, G3 (26)	50%	42%
			G2: 36	86%	60%
	SOF + RBV	16	G3: 64	30%	19%
			95 treatment experienced with G2, G3 (32)	73%	66%
			G2: 32	94%	78%
VALENCE[38]	SOF + RBV	12	G3: 63	62%	61%
			73 patients with G2 (10)	93%	90%
			Treatment naïve G2: 32	97%	100%
	SOF + RBV	24	Treatment experienced G2: 41	90%	88%
			250 patients with G3: (58)	85%	67%
			Treatment naïve G3: 105	93%	92%
			Treatment experienced G3: 145	79%	60%

SOF: Sofosbuvir; Peg IFN: Pegylated interferon alfa-2a; RBV: Ribavirin; G: Hepatitis C virus genotype; SVR: Sustained virologic response.